Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on MiNK Therapeutics. The associated price target remains the same with $35.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Emily Bodnar’s rating is based on the promising clinical results demonstrated by MiNK Therapeutics’ treatment, agenT-797, in combination with nivolumab. The case of a testicular cancer patient achieving complete remission for over two years following a single dose of this treatment highlights its potential efficacy. This outcome is particularly noteworthy as the patient had previously not responded to other treatments, including multiple immune checkpoint inhibitors.
Furthermore, the treatment was well tolerated, with no severe side effects such as cytokine release syndrome or graft-versus-host disease observed. The observed increase in IFN-γ, a key cytokine secreted by iNKT cells, suggests the activity of agenT-797 post-infusion. Additionally, the ongoing Phase 2 trial results in gastric cancer patients, showing survival rates surpassing previous benchmarks, further support the positive outlook for MiNK Therapeutics. These factors collectively contribute to the Buy rating.